GLP-1 Medications May Reduce Cancer Progression, Study Says

Key Points:

• New research from the Cleveland Clinic suggests GLP-1 medications may reduce metastatic cancer progression in patients with Type 2 diabetes or obesity, with significant reductions observed in lung, breast, colorectal, and liver cancers; findings will be presented at the 2026 ASCO meeting.
• The study compared cancer progression in patients taking GLP-1 drugs versus those on DPP-4 inhibitors, finding lower metastasis rates in six of seven obesity-related cancers, though kidney cancer showed no benefit.
• Researchers noted high GLP-1 receptor levels in some cancer cells correlated with a 33% lower risk of death, indicating a possible direct effect of GLP-1s on tumors, but the observational nature of the study means causation is not confirmed.
• Experts caution that GLP-1 drugs are not currently approved for cancer prevention or treatment, and more rigorous randomized trials are needed before these medications can be recommended for oncology use.
• While GLP-1s have known benefits for diabetes, weight loss, and cardiovascular health, their potential anti-cancer effects are an emerging area of research, with ongoing studies needed to clarify their role in cancer care.